ES2690792T3 - Vacunación por medio de levadura recombinante mediante generación de una respuesta inmunitaria humoral protectora contra antígenos definidos - Google Patents
Vacunación por medio de levadura recombinante mediante generación de una respuesta inmunitaria humoral protectora contra antígenos definidos Download PDFInfo
- Publication number
- ES2690792T3 ES2690792T3 ES12823073.7T ES12823073T ES2690792T3 ES 2690792 T3 ES2690792 T3 ES 2690792T3 ES 12823073 T ES12823073 T ES 12823073T ES 2690792 T3 ES2690792 T3 ES 2690792T3
- Authority
- ES
- Spain
- Prior art keywords
- yeast
- thr
- leu
- recombinant
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102011121069A DE102011121069A1 (de) | 2011-12-13 | 2011-12-13 | Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene |
| DE102011121069 | 2011-12-13 | ||
| PCT/DE2012/001205 WO2013107436A1 (de) | 2011-12-13 | 2012-12-12 | Vakzinierung mittels rekombinanter hefe durch erzeugung einer protektiven humoralen immunantwort gegen definierte antigene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2690792T3 true ES2690792T3 (es) | 2018-11-22 |
Family
ID=47681476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12823073.7T Active ES2690792T3 (es) | 2011-12-13 | 2012-12-12 | Vacunación por medio de levadura recombinante mediante generación de una respuesta inmunitaria humoral protectora contra antígenos definidos |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11065312B2 (enExample) |
| EP (1) | EP2844759B1 (enExample) |
| JP (1) | JP6313215B2 (enExample) |
| KR (1) | KR102027400B1 (enExample) |
| CN (1) | CN104428417B (enExample) |
| BR (1) | BR112014014390B1 (enExample) |
| CA (1) | CA2859231C (enExample) |
| DE (2) | DE102011121069A1 (enExample) |
| DK (1) | DK2844759T3 (enExample) |
| ES (1) | ES2690792T3 (enExample) |
| MX (1) | MX368484B (enExample) |
| PL (1) | PL2844759T3 (enExample) |
| RU (1) | RU2630620C2 (enExample) |
| WO (1) | WO2013107436A1 (enExample) |
| ZA (1) | ZA201405034B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102017012109A1 (de) * | 2017-12-27 | 2019-06-27 | Martin-Luther-Universität Halle-Wittenberg | Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis |
| CN109467606A (zh) * | 2018-11-15 | 2019-03-15 | 大连理工大学 | 一种大肠杆菌肠毒素STa-LTB-STb融合蛋白及其编码基因和应用 |
| JP7372647B2 (ja) * | 2019-06-27 | 2023-11-01 | 国立研究開発法人農業・食品産業技術総合研究機構 | α‐リノレン酸産生能が向上した酵母またはその培養物 |
| CN110646614B (zh) * | 2019-07-15 | 2023-05-23 | 新乡学院 | Ibdv抗体的elisa试剂盒和测试方法、有效抗体效价确定方法 |
| CN114870006B (zh) * | 2022-04-13 | 2026-06-02 | 河北农业大学 | 一种etec疫苗及其应用 |
| WO2026119376A1 (de) | 2024-12-03 | 2026-06-11 | Verovaccines Gmbh | Sedimentations-stabilisierte formulierungen für hefe-basierte vakzine |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU643216B2 (en) * | 1989-05-30 | 1993-11-11 | Commonwealth Scientific And Industrial Research Organisation | Production of IBDV VP2 in highly immunogenic form |
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| US6234977B1 (en) | 2000-01-28 | 2001-05-22 | Michael Christy | Variable-force monofilament sensory device and methods of using same |
| AU2002225681A1 (en) | 2000-11-15 | 2002-05-27 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
| KR101085310B1 (ko) * | 2003-03-24 | 2011-11-22 | 인터벳 인터내셔널 비.브이. | 감염성 점액낭병 바이러스 돌연변이체 및 백신 |
| ES2242542B1 (es) * | 2004-04-30 | 2006-12-16 | Consejo Superior De Investigaciones Cientificas | Procedimiento para la produccion en levaduras de capsidas virales vacias compuestas por proteinas derivadas de pvp2 del virus causante de la enfermedad de la bursitis infecciosa (ibdv). |
| WO2006078318A2 (en) * | 2004-07-29 | 2006-07-27 | Novartis Vaccines And Diagnostics Inc. | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
| KR20070068460A (ko) | 2004-10-18 | 2007-06-29 | 글로브이뮨 | 만성 ｃ형 간염에 대한 효모계 치료 |
| CA2638815A1 (en) | 2006-02-02 | 2007-08-16 | Globeimmune, Inc. | Yeast-based vaccine for inducing an immune response |
| WO2008153339A2 (en) * | 2007-06-12 | 2008-12-18 | Univ Sungkyunkwan Found | A vaccine for treating or preventing pasteurellosis using a yeast surface-expression system |
| DE102008057451A1 (de) * | 2008-11-14 | 2010-05-20 | Martin-Luther-Universität Halle-Wittenberg | Verfahren zur oralen Vakzinierung mittels rekombinanter Hefen |
| CN101638824B (zh) | 2009-03-16 | 2012-08-08 | 浙江双友物流器械股份有限公司 | 一种耐磨织带 |
| US8911722B2 (en) | 2009-09-14 | 2014-12-16 | The Regents Of The University Of Colorado, A Body Corporate | Modulation of yeast-based immunotherapy products and responses |
-
2011
- 2011-12-13 DE DE102011121069A patent/DE102011121069A1/de not_active Ceased
-
2012
- 2012-12-12 MX MX2014007183A patent/MX368484B/es active IP Right Grant
- 2012-12-12 PL PL12823073T patent/PL2844759T3/pl unknown
- 2012-12-12 WO PCT/DE2012/001205 patent/WO2013107436A1/de not_active Ceased
- 2012-12-12 KR KR1020147019123A patent/KR102027400B1/ko active Active
- 2012-12-12 CN CN201280062015.XA patent/CN104428417B/zh active Active
- 2012-12-12 RU RU2014127435A patent/RU2630620C2/ru active
- 2012-12-12 CA CA2859231A patent/CA2859231C/en active Active
- 2012-12-12 JP JP2014546315A patent/JP6313215B2/ja active Active
- 2012-12-12 ES ES12823073.7T patent/ES2690792T3/es active Active
- 2012-12-12 BR BR112014014390-0A patent/BR112014014390B1/pt active IP Right Grant
- 2012-12-12 EP EP12823073.7A patent/EP2844759B1/de active Active
- 2012-12-12 DK DK12823073.7T patent/DK2844759T3/en active
- 2012-12-12 DE DE112012005213.7T patent/DE112012005213A5/de not_active Withdrawn
- 2012-12-12 US US14/364,238 patent/US11065312B2/en active Active
-
2014
- 2014-07-10 ZA ZA2014/05034A patent/ZA201405034B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104428417A (zh) | 2015-03-18 |
| JP2015507472A (ja) | 2015-03-12 |
| PL2844759T3 (pl) | 2019-01-31 |
| MX2014007183A (es) | 2014-11-25 |
| EP2844759B1 (de) | 2018-07-18 |
| DE112012005213A5 (de) | 2014-11-13 |
| US11065312B2 (en) | 2021-07-20 |
| DK2844759T3 (en) | 2018-11-05 |
| RU2630620C2 (ru) | 2017-09-11 |
| CN104428417B (zh) | 2020-05-05 |
| ZA201405034B (en) | 2015-12-23 |
| MX368484B (es) | 2019-10-04 |
| WO2013107436A8 (de) | 2015-01-15 |
| BR112014014390A2 (pt) | 2020-12-08 |
| KR102027400B1 (ko) | 2019-10-04 |
| KR20140105821A (ko) | 2014-09-02 |
| EP2844759A1 (de) | 2015-03-11 |
| RU2014127435A (ru) | 2016-02-10 |
| DE102011121069A1 (de) | 2013-06-13 |
| CA2859231A1 (en) | 2013-07-25 |
| US20150190486A1 (en) | 2015-07-09 |
| WO2013107436A1 (de) | 2013-07-25 |
| CA2859231C (en) | 2019-04-30 |
| JP6313215B2 (ja) | 2018-04-18 |
| BR112014014390B1 (pt) | 2022-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Arnold et al. | Protective vaccination against infectious bursal disease virus with whole recombinant Kluyveromyces lactis yeast expressing the viral VP2 subunit | |
| TWI484034B (zh) | 重組錦鯉疱疹病毒（ｋｈｖ）及預防ｋｈｖ所引起疾病之疫苗 | |
| KR20220031028A (ko) | 아프리카 돼지 열병 백신 | |
| CN109310750B (zh) | 编码传染性喉气管炎病毒和传染性法氏囊病病毒抗原的重组非致病性马立克氏病病毒构建体 | |
| CN109069668A (zh) | 用于眼病的基因疗法 | |
| US20220273785A1 (en) | Modified brucella vaccine strain for the treatment of brucellosis | |
| JP3780256B2 (ja) | 小エビ白斑病症候群（ＷｈｉｔｅＳｐｏｔＳｙｎｄｒｏｍｅ）ウイルスの抗原性蛋白質及びその使用 | |
| KR20120059570A (ko) | 재조합 조류 파라믹소바이러스 백신 및 이의 제조 및 사용 방법 | |
| JP2021500876A (ja) | 複数の異種抗原をコードする組換え非病原性マレック病ウイルス構築物 | |
| US11065312B2 (en) | Vaccination by means of recombinant yeast by producing a protective humoral immune response against defined antigens | |
| US20230151387A1 (en) | Covid-19 vaccine based on the myxoma virus platform | |
| JP2023166412A (ja) | 一価及び多価サブユニット予防ワクチン製造のために最適化した、酵母クルイベロマイセス・ラクティスベースの宿主／ベクターシステム | |
| CN119331732A (zh) | 一种基因缺失的重组弓形虫虫株疫苗及其构建方法 | |
| CN109303916A (zh) | 焦亡相关蛋白gsdmd在制备菌蜕疫苗中的应用 | |
| CN101638661B (zh) | 新城疫病毒hn基因和f基因重组乳酸菌的构建 | |
| WO2022101456A1 (en) | Yeast platform for the production of vaccines | |
| US20240158763A1 (en) | Optimal production of sars-cov-2 virus-like particles (vlps) produced in mammalian cells | |
| RU2812347C1 (ru) | Способ получения бактериального продуцента рекомбинантного белка нуклеокапсида nc вируса sars-cov-2 | |
| EP1578791B1 (en) | Inclusion bodies for the oral vaccination of animals | |
| NL2030423B1 (en) | Replication-deficient strain of canine distemper virus and construction method thereof | |
| Grilló et al. | A modified brucella vaccine strain for the treatment of brucellosis | |
| KR101560793B1 (ko) | 비병원성 전염성낭병 변이 바이러스 및 이의 백신으로써의 용도 | |
| EA045050B1 (ru) | Оптимизированная система вектор-хозяин для получения защитной моно- и поливалентной субъединичной вакцины на основе дрожжей kluyveromyces lactis | |
| PL199189B1 (pl) | Szczepionka doustna i nowe zastosowanie drożdży zdolnych do ekspresji antygenu |